![Peter Radovich](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Radovich
Präsident bei
MIRUM PHARMACEUTICALS, INC.
Vermögen: 6 Mio $ am 31.05.2026
Profil
Peter Radovich is President & Chief Operating Officer at Mirum Pharmaceuticals, Inc. since 2024, with employment at the firm starting in 2020.
Former roles include Independent Director at Rain Oncology, Inc. from 2018 to 2024; Senior Vice President-Operations at Global Blood Therapeutics, Inc. from 2016 to 2020; Vice President-Global Product Kyprolis at Onyx Pharmaceuticals, Inc. from 2013 to 2014; Senior Director & VP-Program Leadership at Onyx Pharmaceuticals, Inc. from 2004 to 2006; and Principal at Chiron Corp.
from 2004 to 2006.
Education includes an MBA from the University of Washington and undergraduate studies at Texas Christian University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 05.06.2026 | 57’260 ( 0.09% ) | 6 Mio $ | 31.05.2026 |
Aktive Positionen von Peter Radovich
| Unternehmen | Position | Beginn |
|---|---|---|
| MIRUM PHARMACEUTICALS, INC. | Präsident | 16.01.2024 |
Ehemalige bekannte Positionen von Peter Radovich
| Unternehmen | Position | Ende |
|---|---|---|
| RAIN ONCOLOGY INC. | Direktor/Vorstandsmitglied | 25.01.2024 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Geschäftsführer | 01.04.2020 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Corporate Officer/Principal | 01.01.2014 |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Direktor/Vorstandsmitglied | 01.09.2006 |
Chiron Corp.
 Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Corporate Officer/Principal | 01.01.2006 |
Ausbildung von Peter Radovich
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
67
Beziehungen ersten Grades
7
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Chiron Corp.
Chiron Corp. Medical SpecialtiesHealth Technology Provides nucleic acid test for blood screening | Health Technology |
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that provide therapeutics for cancer | Health Technology |
University of Washington
 University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Texas Christian University
 Texas Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which provides treatment and care of sickle cell disease for inherited blood disorder | Health Technology |
Rain Oncology, Inc.
 Rain Oncology, Inc. BiotechnologyHealth Technology Operates as a clinical-stage precision oncology company that develops therapeutics for cancer patients | Health Technology |
Mirum Pharmaceuticals, Inc.
 Mirum Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage therapeutics company developing a novel approach for treating cholestasis liver diseases | Health Technology |
